Chimeric Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Chimeric Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 14.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | N/A | -21 | N/A | -17 | 1 |
| 6/30/2024 | 7 | -13 | -8 | -8 | N/A |
| 3/31/2024 | 10 | -12 | -8 | -8 | N/A |
| 12/31/2023 | 12 | -12 | -8 | -8 | N/A |
| 9/30/2023 | 8 | -19 | -12 | -12 | N/A |
| 6/30/2023 | 5 | -26 | -16 | -16 | N/A |
| 3/31/2023 | 5 | -22 | -18 | -18 | N/A |
| 12/31/2022 | 6 | -18 | -20 | -20 | N/A |
| 9/30/2022 | 4 | -17 | -17 | -16 | N/A |
| 6/30/2022 | 3 | -16 | -14 | -13 | N/A |
| 3/31/2022 | 1 | -19 | -15 | -13 | N/A |
| 12/31/2021 | N/A | -21 | -16 | -13 | N/A |
| 9/30/2021 | N/A | -18 | -15 | -11 | N/A |
| 6/30/2021 | N/A | -15 | -14 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CHM's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if CHM's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if CHM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CHM's revenue is forecast to grow faster than the Australian market.
High Growth Revenue: CHM is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHM's Return on Equity is forecast to be high in 3 years time